X

Trial Profile

Implementation of the Pre-Exposure Prophylaxis (PrEP) to HIV in Brazilian Transgender Women

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 18 Jul 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Emtricitabine/tenofovir disoproxil fumarate (Primary) ; Estradiol valerate; Spironolactone
Indications HIV infections
Focus Therapeutic Use
Acronyms PrEParadas

Most Recent Events

11 Jul 2022 Results of a sub-study assessing the impact of feminizing hormone therapy on tenofovir and emtricitabine plasma pharmacokinetics published in the Journal of Antimicrobial Chemotherapy
21 Jul 2021 Results evaluating the impact of FHT on PrEP pharmacokinetics (PK) in PrEParadas Study presented at the 11th International AIDS Society Conference on HIV Science
21 Jul 2021 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com